Infectious Disease

New household data show recent COVID-19 shots cut at-home spread by 43%, strengthening pharmacist counseling on staying up to date.

Bundibugyo Ebola spreads in DRC and Uganda as the WHO declares a public health emergency of international concern; learn the case counts, travel alerts, and pharmacist readiness steps.

Spencer Durham, PharmD, FCCP, BCPS, BCIDP, discusses why hepatitis B remains an active public health threat.

The approval ends a decades-long gap in care for patients with chronic hepatitis delta virus (HDV) infection, a serious and life-threatening coinfection with hepatitis B that can rapidly progress to cirrhosis, liver cancer, and liver failure.

A large prospective cohort study offers pharmacists and clinicians new data to consider when counseling patients on the long-term value of early antiviral treatment.

Pharmacists can use immunization registry data, collaborative practice agreements, and evidence-based vaccine advocacy to close adult hepatitis B care gaps.

Expert highlights why hepatitis B vaccination remains an urgent priority for adult patients and why the 2-dose Heplisav-B regimen's faster seroprotection offers meaningful public health advantages over the traditional 3-dose series.

Ashlan Kunz Coyne, PharmD, MPH, discusses treating Pseudomonas–Stenotrophomonas coinfections, co-culture insights, and smart empiric therapy amid rising resistance.

Pharmacists push antimicrobial stewardship into clinics and long-term care, tackling antifungal resistance, rapid diagnostics, vaccines, and public health leadership.

Kunz Coyne expresses interest in antimicrobial stewardship discussions at the joint MAD-ID/SIDP meeting as clinicians continue refining their role in practice.

Pharmacists lead antifungal and antibiotic stewardship beyond hospitals, using rapid diagnostics, vaccines, and equity to curb resistance.

Recent randomized trials and CDC guidance support doxycycline postexposure prophylaxis as a targeted strategy to reduce bacterial STIs in high-risk populations.

Hirsch shows how mentorship and networks shape a pharmacist-scientist, driving infectious disease research and fosfomycin breakthroughs.

Marilyn Bulloch, PharmD, discusses the persistent burden of hepatitis B, evolving adult vaccination recommendations, and how pharmacists can improve vaccine uptake through accessible, stigma-free patient counseling.

New findings reveal that mouse liver cells can form the viral template behind chronic HBV infection.

Ivermectin, vitamin D, and zinc are being recommended on social media as treatment for hantavirus—despite a lack of evidence.

A new study describes the high symptom burden carried by pediatric long COVID patients and highlights integrative medicine's role in their care.

The World Health Organization confirmed the outbreak is the Andes strain, the only known human transmissible hantavirus.

FDA leaders reportedly delay vaccine safety findings on COVID-19 and shingles shots, raising transparency concerns and new challenges for pharmacists.

A hantavirus outbreak aboard a cruise ship is raising urgent concerns about the dangers of this rare but deadly rodent-borne virus.

New trials show Pfizer’s Paxlovid (nirmatrelvir-ritonavir) speeds COVID-19 recovery in vaccinated patients, while hospitalization benefits fade.

Delaying hepatitis B vaccination beyond birth increases preventable infections, liver cancer deaths, and costs.

A large multicohort analysis highlights obesity as a modifiable risk factor for severe infectious outcomes, reinforcing the pharmacist’s role in prevention, vaccination, and chronic disease management.

The approval of doravirine and islatravir marks a new 2-drug, once-daily oral option for HIV-1 management, with implications for treatment simplification, adherence, and pharmacist-led antiretroviral care.

High pneumococcal community-acquired pneumonia burden in older adults highlights the critical role of pharmacists in driving 21-valent vaccine uptake and patient-centered prevention strategies.